Left atrial appendage closure for stroke prevention in atrial fibrillation patients: A promise that came true.
Xi JiangQingsong XiongYuehui YinZhiyu LingPublished in: Pacing and clinical electrophysiology : PACE (2023)
Anticoagulation therapy plays a crucial role in the management of atrial fibrillation (AF), considering the high morbidity and mortality of AF-related ischemic strokes. With the plausible hypothesis that left atrial appendage is the main source of thrombus in AF patients, left atrial appendage closure (LAAC) has been regarded as a potential substitute to oral anticoagulation in order to meet the unmet needs for stroke prevention, particularly in patients with high bleeding risk. Notable advancements in safety, efficacy, and device innovation have been made in recent years, albeit concerns still remain regarding the insufficient efficacy data, device-related complications, and the need for procedural optimization. We aim to review current knowledge about LAAC and provide potential future directions for the remaining key issues.
Keyphrases
- atrial fibrillation
- left atrial appendage
- catheter ablation
- oral anticoagulants
- left atrial
- direct oral anticoagulants
- heart failure
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- stem cells
- risk assessment
- venous thromboembolism
- peritoneal dialysis
- machine learning
- risk factors
- deep learning
- bone marrow
- subarachnoid hemorrhage
- cell therapy
- acute coronary syndrome
- human health